Eliminating “Immune Fog” Shows Promise in Cancer Interception

As scientists race to find effective treatments against cancer, others are working to address tumors before they progress into full-blown cancers. A recent study conducted in the UK has found a possible way to stop cancer in its tracks during its initial stages.

Cancer interception is attracting plenty of research attention, and breakthroughs like these are helping to give the new field increasing prominence in the scientific community. Given that some mice still developed lung cancer even after being treated to clear the immune fog, advanced immunotherapies being developed by firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) can possibly help those&

Read More>>

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

You May Also Be Interested In

• ORANGE COUNTY TEAMSTERS LAUNCH UNFAIR LABOR PRACTICE STRIKE
• Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
• Meed Announces Conditional Acceptance by the TSXV of Qualifying Transaction with Athos Metals and Closing of Second Tranche of Concurrent Financing